FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
dated January 05, 2024
Commission File Number 0-51504
GENETIC TECHNOLOGIES LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrant’s Name)
60-66 Hanover Street
Fitzroy
Victoria 3065 Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: January 05, 2024
GENETIC TECHNOLOGIES LIMITED | ||
By: | /s/ Tony Di Pietro | |
Name: | Tony Di Pietro | |
Title: | Company Secretary |
2 |
EXHIBIT INDEX
Exhibit | Description of Exhibit | |
99.1 |
Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement |
3 |
Exhibit 99.1
Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement
Melbourne, Australia, 5 January 2024 (Global Newswire): Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness, and serious disease, advises that it has received formal notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously disclosed, the Company received a written notice from Nasdaq on July 17, 2023, notifying the Company that it had failed to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market.
To regain compliance with the Listing Rule, the Company’s American Depositary Shares (ADS) were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on December 28, 2023. Nasdaq has stated that this matter is now closed.
Enquiries
Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
Genetic Technologies Limited |
60-66 Hanover Street |
|||
www.genetype.com |
Fitzroy Victoria 3065 |
|||
info@gtglabs.com |
Australia+61 3 8412 7000 |
|||
ABN 17 009 212 328 |
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end